Prognostic value of transient ischemic dilation with regadenoson myocardial perfusion imaging.
Transient ischemic dilation (TID) of the left ventricle seen on myocardial perfusion imaging (MPI) is sometimes used as a marker of severe coronary artery disease. The prognostic value of TID obtained using regadenoson, a selective adenosine A2A receptor agonist, as a stress agent for MPI has not been studied.



TID ratio was measured using an automated software program on consecutive patients with normal and abnormal perfusion pattern on regadenoson MPI at a single institution. An abnormal TID was defined as greater than 1.33. The primary outcome was a composite of cardiac death, non-fatal myocardial infarction (MI), and late coronary revascularization (CR, >90 days after MPI).



The study population consisted of 887 patients (62 ± 12 years, 66% male, 48% diabetes, 46% prior CR, 75% with abnormal perfusion pattern, left ventricular ejection fraction-LVEF 55 ± 6%). An abnormal TID was present in 51 (6%) patients. Baseline characteristics were not different based on the presence or absence of TID. Early CR (≤90 days) was performed in 11 (22%) patients with vs 92 (11%) patients without TID (P = .04). During a mean follow-up of 29 ± 19 months, the primary outcome occurred in 271 (31%) patients (22% cardiac death, 6% MI, 9% late CR). TID was associated with increased risk of the primary outcome (log-rank P = .017), an association largely driven by late CR. In a Cox proportional model adjusted for multiple variables including perfusion defect size (PDS) and LVEF, the hazard ratio for TID was 1.92 (95% CI 1.20-3.08, P = .007). In the subset of patients with normal perfusion pattern, there was no association between TID and outcomes.



TID on regadenoson MPI carries important prognostic information that is independent from PDS and LVEF, but this association is restricted to patients with abnormal perfusion on imaging.
University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA.
Davis
D
Lester
Division of Cardiovascular Disease, University of Alabama at Birmingham, Lyons Harrison Research Building 306, 1720 2nd AVE S, Birmingham, AL, 35294-0007, USA.
Stephanie
S
El-Hajj
Division of Cardiovascular Disease, University of Alabama at Birmingham, Lyons Harrison Research Building 306, 1720 2nd AVE S, Birmingham, AL, 35294-0007, USA.
Ayman A
AA
Farag
Division of Molecular Imaging and Therapeutics, University of Alabama at Birmingham, Birmingham, AL, USA.
Pradeep
P
Bhambhvani
Division of Cardiovascular Disease, University of Alabama at Birmingham, Lyons Harrison Research Building 306, 1720 2nd AVE S, Birmingham, AL, 35294-0007, USA.
Lindsey
L
Tauxe
Division of Cardiovascular Disease, University of Alabama at Birmingham, Lyons Harrison Research Building 306, 1720 2nd AVE S, Birmingham, AL, 35294-0007, USA.
Jaekyeong
J
Heo
Division of Cardiovascular Disease, University of Alabama at Birmingham, Lyons Harrison Research Building 306, 1720 2nd AVE S, Birmingham, AL, 35294-0007, USA.
Ami E
AE
Iskandrian
Division of Cardiovascular Disease, University of Alabama at Birmingham, Lyons Harrison Research Building 306, 1720 2nd AVE S, Birmingham, AL, 35294-0007, USA. fadihage@uab.edu.|Section of Cardiology, Birmingham Veterans Affairs Medical Center, Birmingham, AL, USA. fadihage@uab.edu.
Fadi G
FG
Hage
D005080:Exercise Test / Q000379:methods*; D006801:Humans; D017379:Hypertrophy, Left Ventricular / Q000150:complications / Q000000981:diagnostic imaging*; D007089:Image Enhancement / Q000379:methods*; D017202:Myocardial Ischemia / Q000150:complications / Q000000981:diagnostic imaging*; D055414:Myocardial Perfusion Imaging / Q000379:methods*; D011379:Prognosis; D011687:Purines; D011720:Pyrazoles; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D015899:Tomography, Emission-Computed, Single-Photon / Q000379:methods*; D014665:Vasodilator Agents
D011687:Purines; D011720:Pyrazoles; D014665:Vasodilator Agents; C430916:regadenoson
Myocardial perfusion imaging; outcomes; regadenoson; transient ischemic dilation